scholarly article | Q13442814 |
P50 | author | David Johnson | Q37840488 |
Philip Clarke | Q38590660 | ||
Paolo Ferrari | Q43269545 | ||
Carmel Hawley | Q46863719 | ||
Sunil Badve | Q47145679 | ||
Alan Cass | Q59553032 | ||
Jeff S Coombes | Q60994552 | ||
Donna Reidlinger | Q61650143 | ||
Kim Dalziel | Q61650144 | ||
P2093 | author name string | Lei Zhang | |
Rowan Walker | |||
Vlado Perkovic | |||
Stephen P McDonald | |||
Elaine M Pascoe | |||
Eugenie Pedagogos | |||
Liza A Vergara | |||
Alicia T Morrish | |||
Anish Scaria | |||
On Behalf Of The Hero Study Collaborative Group | |||
P2860 | cites work | Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? | Q27023641 |
Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia | Q28591239 | ||
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial | Q33356816 | ||
Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines | Q34973977 | ||
Prevalence of anemia in chronic kidney disease in the United States | Q35083495 | ||
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome | Q35155017 | ||
Anaemia and inflammation: what are the implications for the nephrologist? | Q35579864 | ||
Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? | Q36218016 | ||
Oxidative stress and inflammation are associated with adiposity in moderate to severe CKD. | Q36667201 | ||
Red blood cell and plasma glutathione peroxidase activities and selenium concentration in patients with chronic kidney disease: a review | Q36679271 | ||
Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia | Q37207365 | ||
Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients | Q37422416 | ||
Ascorbic acid for anemia management in hemodialysis patients: a systematic review and meta-analysis | Q37603998 | ||
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis | Q43586164 | ||
Do different dialytic techniques have different atherosclerotic and antioxidant activities? | Q43749899 | ||
Pentoxifylline improves hemoglobin levels in patients with erythropoietin-resistant anemia in renal failure | Q44948985 | ||
Automated assays for superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activity. | Q46006452 | ||
Antioxidant therapy does not ameliorate oxidative stress and inflammation in patients with end-stage renal disease. | Q46035400 | ||
Influence of oxidative stress and inflammation on rHuEPO requirements of hemodialysis patients with CRP values "in normal range". | Q46843946 | ||
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial | Q48068592 | ||
Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. | Q50521941 | ||
Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. | Q51052485 | ||
Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. | Q53532398 | ||
Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes | Q57396250 | ||
Determination of carbonyl content in oxidatively modified proteins | Q68161213 | ||
Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients | Q73136889 | ||
What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? | Q80554323 | ||
KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target | Q80845843 | ||
The influence of vitamin E supplementation on erythropoietin responsiveness in chronic hemodialysis patients with low levels of erythrocyte superoxide dismutase | Q83974875 | ||
Association between biomarkers of carbonyl stress with increased systemic inflammatory response in different stages of chronic kidney disease and after renal transplantation | Q84576515 | ||
Optimized method for quantification of total F(2)-isoprostanes using gas chromatography-tandem mass spectrometry | Q87015771 | ||
Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients | Q87113230 | ||
P433 | issue | 1 | |
P921 | main subject | pentoxifylline | Q416331 |
chronic renal insufficiency | Q736715 | ||
erythropoiesis-stimulating agent | Q1363798 | ||
P304 | page(s) | 14-23 | |
P577 | publication date | 2016-01-01 | |
P1433 | published in | Redox Report | Q15758836 |
P1476 | title | The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial | |
P478 | volume | 21 |
Q26775058 | The molecular mechanisms of hemodialysis vascular access failure | cites work | P2860 |
Search more.